Clinigen initiates a Managed Access Program for relugolix in Europe for the treatment of advanced hormone-sensitive prostate cancer
20 déc. 2022 02h00 HE
|
Clinigen
20 December 2022 Clinigen initiates a Managed Access Program for relugolix in Europe for the treatment of advanced hormone-sensitive prostate cancer Clinigen Limited (‘Clinigen’), the global...